Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05374395 · ClinicalTrials.gov registry record · NA

Enhancing Substance Use Treatment Services to Decrease Dropout and Improve Outpatient Treatment Utilization in Emerging Adults

A NA study of Substance Use Disorders, sponsored by UConn Health.

Active
Registry status
NA
Development phase
11
Enrollment target
1
Study location

NCT05374395: Active NA study of Substance Use Disorders, sponsored by UConn Health.

NCT05374395 is a NA study of Substance Use Disorders that is active but no longer recruiting, run by UConn Health. The registered enrollment target is 11 participants, below the 500-participant average among 93 other Substance Use Disorders trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05374395, a NA study of Substance Use Disorders, is active but no longer recruiting, sponsored by UConn Health.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
11 participants
Enrollment target
1
Study location

Study Summary

Emerging adults (ages 18-25) are at higher risk for substance use disorders, including opiate addiction, than any other age group but are also more likely to drop out early from substance use treatment services. This project will evaluate an enhancement to usual services, delivered by peer recovery supports, specifically aimed at improving treatment adherence and reducing dropout in this age group. The study will also answer key questions about risk factors for dropout among emerging adults and the financial sustainability of enhancing services to reduce dropout.

Primary Outcome

Data will come from de-identified clinical charts. Dropout will be defined in two ways: 1) patient did not complete the total number of sessions prescribed in the treatment plan and 2) patient was in treatment for less than 90 days.

Conditions Studied

Interventions

  • BEHAVIORAL Peer Recovery Support-Delivered Dropout Prevention enhancement

Study Locations (1)

Connecticut

  • UConn Health - Farmington

Trial Details

FieldValue
Enrollment Target 11 participants
Start Date 2023-07-01
Est. Completion 2027-02-28
Phase NA
UConn Health

178 total trials

What the registry record for NCT05374395 still lists

NCT05374395 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 500-participant average among 93 other Substance Use Disorders trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Substance Use Disorders appearing as the primary indexed condition, and to 1 intervention - of which Peer Recovery Support-Delivered Dropout Prevention enhancement is the first listed.

NCT05374395 reports a single indexed study location in Connecticut.

Frequently Asked Questions

What is clinical trial NCT05374395 about?

NCT05374395 is a clinical study titled "Enhancing Substance Use Treatment Services to Decrease Dropout and Improve Outpatient Treatment Utilization in Emerging Adults". Emerging adults (ages 18-25) are at higher risk for substance use disorders, including opiate addiction, than any other age group but are also more likely to drop out early from substance use treatment services. This project will evaluate an enhancement to usual services, delivered by peer recovery ...

What is the current status of trial NCT05374395?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 11 participants. The study started on 2023-07-01. Estimated completion is 2027-02-28.

What conditions does trial NCT05374395 study?

This clinical trial studies the following conditions: Substance Use Disorders.

What interventions are being tested in trial NCT05374395?

The interventions under investigation include: Peer Recovery Support-Delivered Dropout Prevention enhancement (BEHAVIORAL).

Who is sponsoring clinical trial NCT05374395?

This trial is sponsored by UConn Health, which has 178 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05374395 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Substance Use Disorders

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05374395's enrollment target sits among peer trials

11 92nd of 93 higher than 2 of 93 other Substance Use Disorders trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Substance Use Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03114462 · 11 participants · Phase 1

    Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer

  • NCT06039709 · 11 participants · Phase 1

    Sonodynamic Therapy in Patients With Recurrent GBM

  • NCT06425380 · 11 participants · NA

    Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy

  • NCT06472661 · 11 participants · Early Phase 1

    FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05374395, the US trial registry maintained by the National Library of Medicine. NCT05374395 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.